Literature DB >> 28355620

Imported dengue fever in East London: a 6-year retrospective observational study.

Anna Riddell1, Zahir Osman Eltahir Babiker2.   

Abstract

Background: Dengue fever (DF) is a frequently imported arthropod-borne infection in the United Kingdom but its broad range of clinical presentations makes it potentially unrecognized by clinicians.
Methods: We conducted a 6-year retrospective case note review of laboratory confirmed DF patients in East London in the period from 1 January 2010 through 31 December 2015. Epidemiological, clinical and laboratory features of imported DF were described. Risk factors associated with viraemic DF presentations were assessed.
Results: Forty-four patients (4 from primary care clinics and 40 from three acute hospitals) were confirmed to have DF through RNA and/or IgM detection. In total, 86.4% (38/44) had primary infection compared to 13.6% (6/44) with secondary infection. Viraemic DF presentations accounted for 59.1% (26/44) of cases. The median age was 34 years (IQR 25-43). Most patients were males (68.2%, 30/44) and of non-white ethnicity (81.8%, 36/44). South Asia was the most frequent travel destination (52.3%, 23/44) followed by Southeast Asia (20.5%, 9/44). July-September was the peak season of presentation (43.2%, 19/44). The median interval between arrival in the UK and laboratory testing was 7 days (IQR 4-13). Arriving from abroad ≤ 7 days before molecular testing (age-adjusted odds ratios [OR] 16.98, 95% CI 2.43-118.75, P  =   0.004) and travel to South or Southeast Asia regions (age-adjusted OR 4.41, 95% CI 1.07-18.21, P  =   0.040) were associated with detectable viraemia at presentation. Only one DF patient met the WHO severity criteria. HIV serostatus was determined in 61.4% (27/44) of cases.
Conclusion: Clinicians need to improve DF recognition as well as rates of HIV testing in tropical travellers. Region of travel and time since arrival from DF endemic settings may help clinicians optimize requests for molecular testing. Further research on the clinical and public health aspects of imported DF is needed. © International Society of Travel Medicine, 2017. Published by Oxford University Press. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com

Entities:  

Keywords:  Dengue fever; United Kingdom; clinical features; travellers; viraemia

Mesh:

Year:  2017        PMID: 28355620     DOI: 10.1093/jtm/tax015

Source DB:  PubMed          Journal:  J Travel Med        ISSN: 1195-1982            Impact factor:   8.490


  10 in total

Review 1.  Historical discourse on the development of the live attenuated tetravalent dengue vaccine candidate TV003/TV005.

Authors:  Anna P Durbin
Journal:  Curr Opin Virol       Date:  2020-10-23       Impact factor: 7.090

2.  Novel tools for the surveillance and control of dengue: findings by the DengueTools research consortium.

Authors:  Annelies Wilder-Smith; Hasitha Tissera; Sazaly AbuBakar; Pattamaporn Kittayapong; James Logan; Andreas Neumayr; Joacim Rocklöv; Peter Byass; Valérie R Louis; Yesim Tozan; Eduardo Massad; Raman Preet
Journal:  Glob Health Action       Date:  2018       Impact factor: 2.640

3.  Incidence of Guillain-Barré Syndrome (GBS) in Latin America and the Caribbean before and during the 2015-2016 Zika virus epidemic: A systematic review and meta-analysis.

Authors:  Ariadna Capasso; Danielle C Ompad; Dorice L Vieira; Annelies Wilder-Smith; Yesim Tozan
Journal:  PLoS Negl Trop Dis       Date:  2019-08-26

4.  Estimating the proportion of vaccine-induced hospitalized dengue cases among Dengvaxia vaccinees in the Philippines.

Authors:  Stefan Flasche; Annelies Wilder-Smith; Joachim Hombach; Peter G Smith
Journal:  Wellcome Open Res       Date:  2019-10-31

Review 5.  What Is the Impact of Lockdowns on Dengue?

Authors:  Oliver Brady; Annelies Wilder-Smith
Journal:  Curr Infect Dis Rep       Date:  2021-01-21       Impact factor: 3.663

Review 6.  Dengue vaccine development: status and future.

Authors:  Annelies Wilder-Smith
Journal:  Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz       Date:  2020-01       Impact factor: 1.513

7.  Serum chymase levels correlate with severe dengue warning signs and clinical fluid accumulation in hospitalized pediatric patients.

Authors:  Abhay P S Rathore; Manouri Senanayake; Arjuna Salinda Athapathu; Sunethra Gunasena; Irantha Karunaratna; Wei Yee Leong; Ting Lim; Chinmay Kumar Mantri; Annelies Wilder-Smith; Ashley L St John
Journal:  Sci Rep       Date:  2020-07-16       Impact factor: 4.379

8.  Rapid diagnostic tests for determining dengue serostatus: a systematic review and key informant interviews.

Authors:  R Luo; N Fongwen; C Kelly-Cirino; E Harris; A Wilder-Smith; R W Peeling
Journal:  Clin Microbiol Infect       Date:  2019-01-18       Impact factor: 8.067

Review 9.  Dengue vaccine development by the year 2020: challenges and prospects.

Authors:  Annelies Wilder-Smith
Journal:  Curr Opin Virol       Date:  2020-10-18       Impact factor: 7.090

10.  Secondary Analysis of the Efficacy and Safety Trial Data of the Tetravalent Dengue Vaccine in Children and Adolescents in Colombia.

Authors:  Humberto Reynales; Gabriel Carrasquilla; Betzana Zambrano; Margarita Cortés S; Tifany Machabert; Jin Jing; Sophie Pallardy; Owen Haney; Martha Faccini; Juliana Quintero; Fernando Noriega
Journal:  Pediatr Infect Dis J       Date:  2020-04       Impact factor: 3.806

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.